

Enzyme Replacement Therapy Market Size, Share & Trends Analysis Report By Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others), By Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), By End-User (Hospitals, Infusion Centers and Home Healthcare Setting), By Route of Administration (Oral, Parenteral) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Report | 2023-07-27 | 0 pages | Straits Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Global Site License \$5500.00

Report description:

Enzyme Replacement Therapy Market Analysis and Insights

The Enzyme Replacement Therapy Market size is anticipated to reach USD 9.25 Billion in 2023 and it is projected to reach USD 18.42 Billion by 2032, growing at a CAGR of % during the forecast period.

The Global Enzyme Replacement Therapy Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Enzyme Replacement Therapy Market growth, Size report provides a comprehensive analysis of the Healthcare IT industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Experts, Enzyme Replacement Therapy Market includes major suppliers & Independent Consultants among others.
Global Market Scope and Enzyme Replacement Therapy Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Enzyme Replacement Therapy Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Enzyme Replacement Therapy Market Country Level Analysis

The Global Enzyme Replacement Therapy Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Enzyme Replacement Therapy Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Enzyme Replacement Therapy Market

Some of the other major highlights of the demand for Enzyme Replacement Therapy Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Enzyme Replacement Therapy Market during the forecast period.

Shire Plc

Sanofi S.A.

Biomarin Pharmaceutical Inc.

AbbVie

Alexion Pharmaceuticals Inc.

Allergan plc

Horizon Pharma Public Limited Company

Actelion (Janssen)

Recordati Rare Diseases

Protalix Biotherapeutics

Amicus Therapeutics, Inc.

Chiesi Farmaceutici S.P.A.

Digestive Care Inc.

Leadiant Biosciences Inc.

Takeda Pharmaceuticals

Market Segmentation

The Global Enzyme Replacement Therapy Market Share, Demand provides the most up-to-date Healthcare IT industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

By Product

Agalsidase Beta

Imiglucerase

Velaglucerase Alfa

Idursulfase

Galsulfase

Laronidase

Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

By Disease

Gaucher Disease

Fabry Disease

Pompe Disease

Mucopolysaccharidosis

Exocrine Pancreatic Insufficiency (EPI)

Others

By End-User

Hospitals

Infusion Centers and Home Healthcare Setting

By Route of Administration

Oral

Parenteral

Regions Coverd

North America

U.S.

Canada

Europe

U.K.

Germany

France

Spain

Italy

Russia

Nordic

Benelux

Rest of Europe

APAC

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

China
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa

UAE
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM

Brazil
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

- 1 Executive Summary
- 2 Research Scope & Segmentation
 - 2.1 Research Objectives
 - 2.2 Limitations & Assumptions
 - 2.3 Market Scope & Segmentation
 - 2.4 Currency & Pricing Considered

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3 Market Opportunity Assessment
 - 3.1 Emerging Regions / Countries
 - 3.2 Emerging Companies
 - 3.3 Emerging Applications / End Use
- 4 Market Trends
 - 4.1 Drivers
 - 4.2 Market Warning Factors
 - 4.3 Latest Macro Economic Indicators
 - 4.4 Geopolitical Impact
 - 4.5 Technology Factors
- 5 Market Assessment
 - 5.1 Porters Five Forces Analysis
 - 5.2 Value Chain Analysis
- 6 Global Enzyme Replacement Therapy Market Size Analysis
 - 6.1 By Product
 - 6.1.1 Agalsidase Beta
 - 6.1.2 Imiglucerase
 - 6.1.3 Velaglucerase Alfa
 - 6.1.4 Idursulfase
 - 6.1.5 Galsulfase
 - 6.1.6 Laronidase
 - 6.1.7 Others
 - 6.2 By Disease
 - 6.2.1 Gaucher Disease
 - 6.2.2 Fabry Disease
 - 6.2.3 Pompe Disease
 - 6.2.4 Mucopolysaccharidosis
 - 6.2.5 Exocrine Pancreatic Insufficiency (EPI)
 - 6.2.6 Others
 - 6.3 By End-User
 - 6.3.1 Hospitals
 - 6.3.2 Infusion Centers and Home Healthcare Setting
 - 6.4 By Route of Administration
 - 6.4.1 Oral
 - 6.4.2 Parenteral
- 7 North America Market Analysis
 - 7.1 By Product
 - 7.1.1 Agalsidase Beta
 - 7.1.2 Imiglucerase
 - 7.1.3 Velaglucerase Alfa
 - 7.1.4 Idursulfase
 - 7.1.5 Galsulfase
 - 7.1.6 Laronidase
 - 7.1.7 Others
 - 7.2 By Disease
 - 7.2.1 Gaucher Disease
 - 7.2.2 Fabry Disease

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2.3 Pompe Disease
- 7.2.4 Mucopolysaccharidosis
- 7.2.5 Exocrine Pancreatic Insufficiency (EPI)
- 7.2.6 Others
- 7.3 By End-User
- 7.3.1 Hospitals
- 7.3.2 Infusion Centers and Home Healthcare Setting
- 7.4 By Route of Administration
- 7.4.1 Oral
- 7.4.2 Parenteral
- 7.4 U.S.
- 7.5 Canada
- 8 Europe Market Analysis
- 8.1 By Product
- 8.1.1 Agalsidase Beta
- 8.1.2 Imiglucerase
- 8.1.3 Velaglucerase Alfa
- 8.1.4 Idursulfase
- 8.1.5 Galsulfase
- 8.1.6 Laronidase
- 8.1.7 Others
- 8.2 By Disease
- 8.2.1 Gaucher Disease
- 8.2.2 Fabry Disease
- 8.2.3 Pompe Disease
- 8.2.4 Mucopolysaccharidosis
- 8.2.5 Exocrine Pancreatic Insufficiency (EPI)
- 8.2.6 Others
- 8.3 By End-User
- 8.3.1 Hospitals
- 8.3.2 Infusion Centers and Home Healthcare Setting
- 8.4 By Route of Administration
- 8.4.1 Oral
- 8.4.2 Parenteral
- 8.4 U.K.
- 8.5 Germany
- 8.6 France
- 8.7 Spain
- 8.8 Italy
- 8.9 Russia
- 8.10 Nordic
- 8.11 Benelux
- 8.12 Rest of Europe
- 9 APAC Market Analysis
- 9.1 By Product
- 9.1.1 Agalsidase Beta
- 9.1.2 Imiglucerase

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.1.3 Velaglucerase Alfa
- 9.1.4 Idursulfase
- 9.1.5 Galsulfase
- 9.1.6 Laronidase
- 9.1.7 Others
- 9.2 By Disease
 - 9.2.1 Gaucher Disease
 - 9.2.2 Fabry Disease
 - 9.2.3 Pompe Disease
 - 9.2.4 Mucopolysaccharidosis
 - 9.2.5 Exocrine Pancreatic Insufficiency (EPI)
 - 9.2.6 Others
- 9.3 By End-User
 - 9.3.1 Hospitals
 - 9.3.2 Infusion Centers and Home Healthcare Setting
- 9.4 By Route of Administration
 - 9.4.1 Oral
 - 9.4.2 Parenteral
- 9.4 China
- 9.5 Korea
- 9.6 Japan
- 9.7 India
- 9.8 Australia
- 9.9 Taiwan
- 9.10 South East Asia
- 9.11 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
 - 10.1 By Product
 - 10.1.1 Agalsidase Beta
 - 10.1.2 Imiglucerase
 - 10.1.3 Velaglucerase Alfa
 - 10.1.4 Idursulfase
 - 10.1.5 Galsulfase
 - 10.1.6 Laronidase
 - 10.1.7 Others
 - 10.2 By Disease
 - 10.2.1 Gaucher Disease
 - 10.2.2 Fabry Disease
 - 10.2.3 Pompe Disease
 - 10.2.4 Mucopolysaccharidosis
 - 10.2.5 Exocrine Pancreatic Insufficiency (EPI)
 - 10.2.6 Others
 - 10.3 By End-User
 - 10.3.1 Hospitals
 - 10.3.2 Infusion Centers and Home Healthcare Setting
 - 10.4 By Route of Administration
 - 10.4.1 Oral

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.4.2 Parenteral
- 10.4 UAE
- 10.5 Turkey
- 10.6 Saudi Arabia
- 10.7 South Africa
- 10.8 Egypt
- 10.9 Nigeria
- 10.10 Rest of MEA
- 11 LATAM Market Analysis
 - 11.1 By Product
 - 11.1.1 Agalsidase Beta
 - 11.1.2 Imiglucerase
 - 11.1.3 Velaglucerase Alfa
 - 11.1.4 Idursulfase
 - 11.1.5 Galsulfase
 - 11.1.6 Laronidase
 - 11.1.7 Others
 - 11.2 By Disease
 - 11.2.1 Gaucher Disease
 - 11.2.2 Fabry Disease
 - 11.2.3 Pompe Disease
 - 11.2.4 Mucopolysaccharidosis
 - 11.2.5 Exocrine Pancreatic Insufficiency (EPI)
 - 11.2.6 Others
 - 11.3 By End-User
 - 11.3.1 Hospitals
 - 11.3.2 Infusion Centers and Home Healthcare Setting
 - 11.4 By Route of Administration
 - 11.4.1 Oral
 - 11.4.2 Parenteral
 - 11.4 Brazil
 - 11.5 Mexico
 - 11.6 Argentina
 - 11.7 Chile
 - 11.8 Colombia
 - 11.9 Rest of LATAM
- 12 Competitive Landscape
 - 12.1 Global Enzyme Replacement Therapy Market Share By Players
 - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
 - 13.1 American International Industries (GIGI)
 - 13.1.1 Overview
 - 13.1.2 Business Information
 - 13.1.3 Revenue
 - 13.1.4 ASP
 - 13.1.5 Swot Analysis
 - 13.1.6 Recent Developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.2 Sanofi S.A.
- 13.3 Biomarin Pharmaceutical Inc.
- 13.4 AbbVie
- 13.5 Alexion Pharmaceuticals Inc.
- 13.6 Allergan plc
- 13.7 Horizon Pharma Public Limited Company
- 13.8 Actelion (Janssen)
- 13.9 Recordati Rare Diseases
- 13.10 Protalix Biotherapeutics
- 13.11 Amicus Therapeutics, Inc.
- 13.12 Chiesi Farmaceutici S.P.A.
- 13.13 Digestive Care Inc.
- 13.14 Leadiant Biosciences Inc.
- 13.15 Takeda Pharmaceuticals
- 14 Research Methodology
 - 14.1 Research Data
 - 14.1.1 Secondary Data
 - 14.1.1.1 Major secondary sources
 - 14.1.1.2 Key data from secondary sources
 - 14.1.2 Primary Data
 - 14.1.2.1 Key data from primary sources
 - 14.1.2.2 Breakdown of primaries
 - 14.1.3 Secondary And Primary Research
 - 14.1.3.1 Key industry insights
 - 14.2 Market Size Estimation
 - 14.2.1 Bottom-Up Approach
 - 14.2.2 Top-Down Approach
 - 14.2.3 Market Projection
 - 14.3 Research Assumptions
 - 14.3.1 Assumptions
 - 14.4 Limitations
 - 14.5 Risk Assessment
- 15 Appendix
 - 15.1 Discussion Guide
 - 15.2 Customization Options
 - 15.3 Related Reports
- 16 Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Enzyme Replacement Therapy Market Size, Share & Trends Analysis Report By Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others), By Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), By End-User (Hospitals, Infusion Centers and Home Healthcare Setting), By Route of Administration (Oral, Parenteral) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Report | 2023-07-27 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Job title*

Company Name*

Address*

Zip Code*

EU Vat / Tax ID / NIP number*

City*

Country*

Date

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com